6.4 New coronavirus pneumonia
At present, COVID-19 is still rampant in many countries around the world and cannot be effectively controlled. Xia[75] et al. Combined with network pharmacology and molecular docking, found that the Lianhua Qingwen capsule (LQC) has a certain curative effect in patients with COVID-19, and AKT1 may be the therapeutic target of COVID-19. Tao[76] and others, through network pharmacology, revealed that baicalein and quercetin may play a therapeutic role in COVID-19 by regulating a variety of signaling pathways through ACE2. In addition, Liu [77] et al. Screened new candidate drugs for the treatment of COVID-19 based on network pharmacology and transcriptomics methods, and identified 18 separate candidate drugs after screening and analysis, including drugs not previously proposed for the treatment of COVID-19, such as nicardipine, planting, tibial and promethazine.